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BrMets was 23% higher ($184,872 vs. $150,931; p0.010) after adjustment for other
factors. The difference was consistent across resources: 25% higher hospitalization
costs $46,871 vs. $37,504; p.082); 23% higher ambulatory costs, ($121,224 vs.
$98,276; p0.033); 23% higher retail pharmacy costs, ($13,282 vs. $10,774; p0.118).
Patients with BrMets averaged more hospitalizations (2.4 vs. 1.9; p0.005), ER visits
(2.7 vs. 2.2; p0.067), and ambulatory encounters (111 vs. 92; p0.005) from initial
NSCLC diagnosis to end of follow-up. CONCLUSIONS: Intensity of resource use and
costs were higher in metastatic NSCLC, especially in BrMets patients. Treatment
that improves disease control could reduce the intensity of cost and resource use
among NSCLC BrMets patients.
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OBJECTIVES: To assess health care resource utilization and costs among patients
with metastatic melanoma in real world practice setting. METHODS: Using a large
US medical claims database, patients were identified between 2005 and 2010 using
2melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and 2 diagnoses for metasta-
sis (ICD-9-CM: 197.xx, 198.xx). The index date was the first date of metastasis
diagnosis. Patients who had other primary malignant tumors prior to the mela-
noma diagnosis, were younger than 18 years old at the index, or had a pre-index
period of less than 6 months, were excluded from the analysis. Patients were fol-
lowed from the index date to death, disenrollment, or end of the study period (June
30, 2010), whichever occurred first. Health care utilization and health care costs
(adjusted to 2010 dollars) were examined per patient-year for office visits, outpa-
tient visits, emergency room (ER) visits and inpatient hospitalization. RESULTS: A
total of 2,546 patients with metastatic melanoma were identified. Mean ( stan-
dard deviation) age at the index was 60.6 ( 14.0) years and 36.5% were female.
Overall, 87.3% of the patients had at least one physician office visit with a mean of
24.0 visits per person-year, 64.7% had an ER visit with a mean of 12.9 visits per
person-year, 90.6% had an outpatient visit with a mean of 8.3 visits per person-
year, and 82.2% had been hospitalized with a mean of 12.4 hospitalizations per
person-year. The mean total costs per patient-year were $117,610, which was
driven mainly by inpatient costs ($60,355/patient-year) and outpatient costs
($34,540/patient-year). CONCLUSIONS: Inpatient and outpatient care are key cost
drivers in the medical management of patients with advanced melanoma.
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OBJECTIVES: Incidence of breast cancer (BC) with brain metastases (BM) is increas-
ing especially among patients with HER2-positive status. Their management is
based on diversified and expensive treatments for which costs data are scarce. We
estimated hospital costs of BCBM and their evolution within a period of two years
following BM diagnosis. METHODS: An observational retrospective multicenter
study was conducted on 207 HER2 breast cancer (BC) patients, newly diagnosed
with brain metastases (BM) as first site of relapse or secondary metastases between
January 2006 and December 2008. Data on patient profile, treatments (neurosur-
gery, radiotherapy, chemotherapy), complications leading to rehospitalisation and
hospitalisation stays were collected. Direct medical costs were estimated from the
Health Insurance perspective using Diagnosis Related Groups (DRGs) official tariffs
and expensive drugs tariffs (2007). Censored treatment cost data were analyzed
using the Bang and Tsiasis method. RESULTS: Patients were treated by radiation
therapy (91.8%), chemotherapy (84.5%) and neurosurgery (12.6%). The mean cost of
management of HER2-positive BCBMs was 18,480€/patient from 0-6 months,
16,306€ from 7-12 months, 15,844€ from 13-18 months and 15,225€ from 19-24
months. The mean cost of the first year following diagnosis was 33,847€/patient.
The proportion of costs attributed to inpatient hospitalizations stay was equal to
the one attributed to expensive drugs whatever the time period of follow-up
(17,153€/patient for hospitalizations vs 16,693€/patient for expensive drugs after
one year of follow-up). Patients with BM as first site of relapse induced more health
care resources compared to patients with secondary BM.CONCLUSIONS:The man-
agement of BCBM generates important health care resources mainly concentrated
within the first months. Health care costs decrease during the follow-up period
while the variability of costs is increasing. These results illustrate the personalized
disease management at the advanced stage of disease. Observational studies are
an interesting opportunity to estimate health care resources and associated costs
more precisely.
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OBJECTIVES: The aim of this prospective, observational, multicenter study was to
estimate the management costs of bone metastatic disease (BMD) in patients with
lung cancer. METHODS: Consecutive patients presenting BMD from lung cancer
diagnosed between May 2006 and May 2007 in 40 centers were enrolled. The natural
course of bone metastatic disease was modeled using a Markov model with 4
health states (asymptomatic patient, symptomatic patient, skeletal-related event
(SRE) and death) and a cycle length of one month, until death or a 5-year period.
Direct medical costs induced by BMD (including symptomatic or therapeutic treat-
ment and hospitalizations) were prospectively collected from the health care pro-
vider’s perspective. RESULTS:Among the 554 patients enrolled (mean age 62 years,
77% of males), 26.7% presented a SRE at diagnosis and 39% during follow-up. The
median survival time was 5.8 months, and the 1- and 2-year survival rates were
22% and 7%, respectively. The main BMD treatments were opiate therapy (78%),
biphosphonates (52%), radiotherapy (42%), and surgery (9%). The mean monthly
BMD treatment costs were 190 €, 374 €, and 4 672 € for asymptomatic patients,
symptomatic patients, and patients with SRE, respectively. The average first-year
BMD management cost was 3 999 €  4 135 (IC95%: 374-15 886), and 49.5% of this
cost was attributable to patients with SRE. CONCLUSIONS: This analysis under-
lines the burden of bone metastatic disease, and particularly of skeletal-related
event in overall treatment costs.
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OBJECTIVES: To assess an economical burden of HPV associated diseases in
Saint-Petersburg. METHODS: Total lifetime costs (direct and indirect) of HPV-asso-
ciated diseases (cervical cancer, cervical dysplasia – CIN I-III, and condylomatosis -
genital warts) in one cohort (13 years old girls in 2010; life expectancy - 74 years;
cohort amount - 16 thousands) were estimated. Epidemiologic forecast was pre-
pared based on mathematical-statistical modeling with least-square method of
regression analysis on parent observation matrix. Raw epidemiologic data on mor-
bidity and mortality were derived from official statistics. Cost of treatment was
calculated using current out-patient and hospital tariffs (in obligatory medical in-
surance program) and standards of treatment (as of 2009). Indirect costs (gross
output underproduction, disability pension, sick-pay etc.) were assessed based on
existing legislation (Federal and Saint-Petersburg’s regional). No discounting was ap-
plied in the analysis. RESULTS: Rates (per 100 000 female population) of dysplasia,
genital warts, and cervical cancer incidence, and death were 16.5, 38.7-59,7, and
13.1-17.3, and 7.1-9.6, respectively. 10 years’ growth of cervical cancer incidence
and mortality was expected to be 12-15% and 8-15% (in different age groups), re-
spectively. Total annual economic burden due to HPV diseases was 822 mln. Rub
which includes: 72 mln. Rub – treatment of cervical cancer, 637 mln. Rub – indirect
costs due to cervical cancer; 89 mln. Rub – dysplasia, 20 mln. Rub – genital warts.
Sum of total cost in one cohort was 1.1 billion Rub. CONCLUSIONS: Economic
burden of HPV-associated diseases in Saint-Petersburg in one cohort expected to be
1.1 billon Rub.
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BACKGROUND: Human papillomavirus (HPV) is the most common sexually trans-
mitted infection and is a well-established cause of anogenital cancers (responsible
for over 70% of cervical cancers). Vaccines that target the HPV strains responsible
for such cancers elicit virus-neutralising antibody responses, thus preventing the
initial infection and some re-infections associated with the same HPV types. Re-
search also suggests that HPV is a risk factor in cancers originating in the upper
aero-digestive tract, known as head and neck (HN) cancers. OBJECTIVES: To es-
timate the prevalence, incidence and associated costs of HPV-related anogenital
and HN cancers in England. METHODS: The Hospital Episode Statistics (HES)
database was used to estimate the prevalence and incidence of anogenital and
head and neck cancers in England from 2002 to 2011. An in-house epidemiologic
study and published sources were used to estimate the proportions of these can-
cers attributable to HPV . Cost estimates using Healthcare Resource Groups (HRGs)
in combination with the most recent UK National Tariff will be applied to the data.
Estimates for costs outside the scope of the National Tariff (such as rehabilitation
costs which, for example, are a key component of HN cancer treatment path-
ways) will be derived from expert opinion using resource use surveys. Results will
be validated by clinical experts in each cancer included in the analysis. RESULTS:
The analyses will highlight key areas of the broader burden of HPV-related cancers
and quantify the associated healthcare costs falling on the NHS in England. A
proportion of HPV-related cancers can be prevented through vaccination, as such,
the analysis aims to capture overall costs and, in turn, the potential for cost offsets
through the implementation of preventative healthcare pathways.CONCLUSIONS:
The use of HPV vaccines has the potential to reduce the incidence of a proportion of
HPV-related cancers, improving patient quality of life in a cost-effective manner.
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